home / stock / stro / stro short
Short Information | Sutro Biopharma Inc. (NASDAQ:STRO)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 2,030,013 |
Total Actual Volume | 21,311,098 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 101,501 |
Average Short Percentage | 11.14% |
Is there a STRO Short Squeeze or Breakout about to happen?
See the STRO Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-19-2024 | $3.76 | $3.765 | $3.815 | $3.65 | 518,899 | 47,858 | 9.22% |
07-18-2024 | $4.01 | $3.72 | $4.11 | $3.715 | 653,119 | 60,860 | 9.32% |
07-17-2024 | $4 | $4.06 | $4.218 | $3.9703 | 790,054 | 64,318 | 8.14% |
07-16-2024 | $4.22 | $4.07 | $4.36 | $4.06 | 1,221,468 | 64,909 | 5.31% |
07-15-2024 | $4.17 | $4.22 | $4.39 | $4.1 | 1,057,341 | 77,496 | 7.33% |
07-12-2024 | $3.95 | $4.16 | $4.43 | $3.85 | 1,151,526 | 129,371 | 11.23% |
07-11-2024 | $3.67 | $3.96 | $3.97 | $3.62 | 1,001,349 | 123,148 | 12.3% |
07-10-2024 | $3.38 | $3.6 | $3.61 | $3.31 | 1,071,236 | 147,876 | 13.8% |
07-09-2024 | $3.03 | $3.36 | $3.425 | $3.015 | 1,137,987 | 220,214 | 19.35% |
07-08-2024 | $2.92 | $3.04 | $3.1 | $2.92 | 650,902 | 81,461 | 12.52% |
07-05-2024 | $2.86 | $2.92 | $2.94 | $2.75 | 667,973 | 92,725 | 13.88% |
07-03-2024 | $2.95 | $2.88 | $3.07 | $2.87 | 414,870 | 44,173 | 10.65% |
07-02-2024 | $3.04 | $2.96 | $3.04 | $2.82 | 621,475 | 135,160 | 21.75% |
07-01-2024 | $2.9 | $3.05 | $3.065 | $2.89 | 1,015,749 | 114,132 | 11.24% |
06-28-2024 | $2.94 | $2.93 | $3.04 | $2.79 | 3,878,990 | 77,609 | 2% |
06-27-2024 | $2.92 | $2.92 | $2.99 | $2.88 | 580,872 | 97,828 | 16.84% |
06-26-2024 | $2.99 | $2.935 | $3.04 | $2.76 | 1,612,839 | 236,694 | 14.68% |
06-25-2024 | $3.08 | $2.99 | $3.095 | $2.955 | 1,040,487 | 71,998 | 6.92% |
06-24-2024 | $3.24 | $3.07 | $3.285 | $3.045 | 635,720 | 77,212 | 12.15% |
06-21-2024 | $3.32 | $3.23 | $3.33 | $3.14 | 1,588,242 | 64,971 | 4.09% |
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Barbara Leyman, Ph.D., a...
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - - Patient expansion phase well underway in Phase 2 study of luvelta in combination with be...
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1 have been enrolled and are in foll...